| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |